Amyloidosis Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

Detailed TOC of Amyloidosis Therapeutics Market by Type and Geography - Global Forecast and Analysis 2019-2023

PART 01: EXECUTIVE SUMMARY         

PART 02: SCOPE OF THE REPORT         

2.1 Preface         

2.2 Preface         

2.3 Currency conversion rates for US$         

PART 03: MARKET LANDSCAPE         

Market ecosystem         

Market characteristics         

Market segmentation analysis         

PART 04: MARKET SIZING         

Market definition         

Market sizing 2018         

Market size and forecast 2018-2023         

PART 05: FIVE FORCES ANALYSIS         

Bargaining power of buyers         

Bargaining power of suppliers         

Threat of new entrants         

Threat of substitutes         

Threat of rivalry         

Market condition         

PART 06: MARKET SEGMENTATION BY TYPE         

Market segmentation by type         

Comparison by type         

Systemic amyloidosis - Market size and forecast 2018-2023         

Other amyloidosis - Market size and forecast 2018-2023         

Market opportunity by type         

PART 07: CUSTOMER LANDSCAPE         

PART 08: GEOGRAPHIC LANDSCAPE         

Geographic segmentation         

Geographic comparison         

North America - Market size and forecast 2018-2023         

Europe - Market size and forecast 2018-2023         

Asia - Market size and forecast 2018-2023         

ROW - Market size and forecast 2018-2023         

Key leading countries         

Market opportunity         

PART 09: DECISION FRAMEWORK         

PART 10: DRIVERS AND CHALLENGES         

Market drivers         

Market challenges         

PART 11: MARKET TRENDS         

Increasing awareness about rare diseases         

Special drug designations         

Strategic alliances         

PART 12: VENDOR LANDSCAPE         

Overview         

Landscape disruption         

PART 13: VENDOR ANALYSIS        

Vendors covered        

Vendor classification        

Market positioning of vendors        

AbbVie Inc.        

Allergan Plc        

Alnylam Pharmaceuticals Inc.        

Amgen Inc.        

Celgene Corp.        

GlaxoSmithKline Plc        

Ionis Pharmaceuticals Inc.        

Johnson & Johnson Services Inc.        

Pfizer Inc.        

Takeda Pharmaceutical Co. Ltd.        

PART 14: APPENDIX        

Research methodology        

List of abbreviations        

Definition of market positioning of vendors        

PART 15: EXPLORE TECHNAVIO        

 

  

Exhibit 01:          Product overview         

Exhibit 02:          Global pharmaceuticals market         

Exhibit 03:          Segments of global pharmaceuticals market         

Exhibit 04:          Market characteristics         

Exhibit 05:          Market segments         

Exhibit 06:          Market definition - Inclusions and exclusions checklist         

Exhibit 07:          Market size 2018         

Exhibit 08:          Global market: Size and forecast 2018-2023 ($ millions)         

Exhibit 09:          Global market: Year-over-year growth 2019-2023 (%)         

Exhibit 10:          Five forces analysis 2018         

Exhibit 11:          Five forces analysis 2023         

Exhibit 12:          Bargaining power of buyers         

Exhibit 13:          Bargaining power of suppliers         

Exhibit 14:          Threat of new entrants         

Exhibit 15:          Threat of substitutes         

Exhibit 16:          Threat of rivalry         

Exhibit 17:          Market condition - Five forces 2018         

Exhibit 18:          Type - Market share 2018-2023 (%)         

Exhibit 19:          Comparison by type         

Exhibit 20:          Systemic amyloidosis - Market size and forecast 2018-2023 ($ millions)         

Exhibit 21:          Systemic amyloidosis - Year-over-year growth 2019-2023 (%)         

Exhibit 22:          Other amyloidosis - Market size and forecast 2018-2023 ($ millions)         

Exhibit 23:          Other amyloidosis - Year-over-year growth 2019-2023 (%)         

Exhibit 24:          Market opportunity by type         

Exhibit 25:          Customer landscape         

Exhibit 26:          Market share by geography 2018-2023 (%)         

Exhibit 27:          Geographic comparison         

Exhibit 28:          North America - Market size and forecast 2018-2023 ($ millions)         

Exhibit 29:          North America - Year-over-year growth 2019-2023 (%)         

Exhibit 30:          Top 3 countries in North America         

Exhibit 31:          Europe - Market size and forecast 2018-2023 ($ millions)         

Exhibit 32:          Europe - Year-over-year growth 2019-2023 (%)         

Exhibit 33:          Top 3 countries in Europe         

Exhibit 34:          Asia - Market size and forecast 2018-2023 ($ millions)         

Exhibit 35:          Proportion of geriatric population in Asia 2009 and 2018         

Exhibit 36:          Asia - Year-over-year growth 2019-2023 (%)         

Exhibit 37:          Top 3 countries in Asia         

Exhibit 38:          ROW - Market size and forecast 2018-2023 ($ millions)         

Exhibit 39:          ROW - Year-over-year growth 2019-2023 (%)         

Exhibit 40:          Top 3 countries in ROW         

Exhibit 41:          Key leading countries         

Exhibit 42:          Market opportunity         

Exhibit 43:          Prevalence/incidence of associated risk factors of amyloidosis         

Exhibit 44:          Growth of geriatric population 2014-2018 (%)         

Exhibit 45:          Cost of approved drugs for treatment of amyloidosis in the US         

Exhibit 46:          Impact of drivers and challenges         

Exhibit 47:          Drug designations         

Exhibit 48:          Vendor landscape         

Exhibit 49:          Landscape disruption         

Exhibit 50:          Vendors covered        

Exhibit 51:          Vendor classification        

Exhibit 52:          Market positioning of vendors        

Exhibit 53:          AbbVie Inc. - Vendor overview        

Exhibit 54:          AbbVie Inc. - Business segments        

Exhibit 55:          AbbVie Inc. - Organizational developments        

Exhibit 56:          AbbVie Inc. - Geographic focus        

Exhibit 57:          AbbVie Inc. - Key offerings        

Exhibit 58:          AbbVie Inc. - Key customers        

Exhibit 59:          Allergan Plc - Vendor overview        

Exhibit 60:          Allergan Plc - Business segments        

Exhibit 61:          Allergan Plc - Organizational developments        

Exhibit 62:          Allergan Plc - Geographic focus        

Exhibit 63:          Allergan Plc - Segment focus        

Exhibit 64:          Allergan Plc - Key offerings        

Exhibit 65:          Allergan Plc - Key customers        

Exhibit 66:          Alnylam Pharmaceuticals Inc. - Vendor overview        

Exhibit 67:          Alnylam Pharmaceuticals Inc. - Business segments        

Exhibit 68:          Alnylam Pharmaceuticals Inc. - Organizational developments        

Exhibit 69:          Alnylam Pharmaceuticals Inc. - Key offerings        

Exhibit 70:          Alnylam Pharmaceuticals Inc. - Key customers        

Exhibit 71:          Amgen Inc. - Vendor overview        

Exhibit 72:          Amgen Inc. - Business segments        

Exhibit 73:          Amgen Inc. - Organizational developments        

Exhibit 74:          Amgen Inc. - Geographic focus        

Exhibit 75:          Amgen Inc. - Key offerings        

Exhibit 76:          Amgen Inc. - Key customers        

Exhibit 77:          Celgene Corp. - Vendor overview        

Exhibit 78:          Celgene Corp. - Business segments        

Exhibit 79:          Celgene Corp. - Organizational developments        

Exhibit 80:          Celgene Corp. - Geographic focus        

Exhibit 81:          Celgene Corp. - Key offerings        

Exhibit 82:          Celgene Corp. - Key customers        

Exhibit 83:          GlaxoSmithKline Plc - Vendor overview        

Exhibit 84:          GlaxoSmithKline Plc - Business segments        

Exhibit 85:          GlaxoSmithKline Plc - Organizational developments        

Exhibit 86:          GlaxoSmithKline Plc - Geographic focus        

Exhibit 87:          GlaxoSmithKline Plc - Segment focus        

Exhibit 88:          GlaxoSmithKline Plc - Key offerings        

Exhibit 89:          GlaxoSmithKline Plc - Key customers        

Exhibit 90:          Ionis Pharmaceuticals Inc. - Vendor overview        

Exhibit 91:          Ionis Pharmaceuticals Inc. - Business segments        

Exhibit 92:          Ionis Pharmaceuticals Inc. - Organizational developments        

Exhibit 93:          Ionis Pharmaceuticals Inc. - Key offerings        

Exhibit 94:          Ionis Pharmaceuticals Inc. - Key customers        

Exhibit 95:          Johnson & Johnson Services Inc. - Vendor overview        

Exhibit 96:          Johnson & Johnson Services Inc. - Business segments        

Exhibit 97:          Johnson & Johnson Services Inc. - Organizational developments        

Exhibit 98:          Johnson & Johnson Services Inc. - Geographic focus        

Exhibit 99:          Johnson & Johnson Services Inc. - Segment focus        

Exhibit 100:          Johnson & Johnson Services Inc. - Key offerings        

Exhibit 101:          Johnson & Johnson Services Inc. - Key customers        

Exhibit 102:          Pfizer Inc. - Vendor overview        

Exhibit 103:          Pfizer Inc. - Business segments        

Exhibit 104:          Pfizer Inc. - Organizational developments        

Exhibit 105:          Pfizer Inc. - Geographic focus        

Exhibit 106:          Pfizer Inc. - Segment focus        

Exhibit 107:          Pfizer Inc. - Key offerings        

Exhibit 108:          Pfizer Inc. - Key customers        

Exhibit 109:          Takeda Pharmaceutical Co. Ltd. - Vendor overview        

Exhibit 110:          Takeda Pharmaceutical Co. Ltd. - Business segments        

Exhibit 111:          Takeda Pharmaceutical Co. Ltd. - Organizational developments        

Exhibit 112:          Takeda Pharmaceutical Co. Ltd. - Geographic focus        

Exhibit 113:          Takeda Pharmaceutical Co. Ltd. - Key offerings        

Exhibit 114:          Takeda Pharmaceutical Co. Ltd. - Key customers        

Exhibit 115:          Validation techniques employed for market sizing        

Exhibit 116:          Definition of market positioning of vendors